Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Mucosal Melanoma

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related cancers:

‹

Melanoma (1043)

Ocular Melanoma (111)

Uveal Melanoma (106)

Cutaneous Melanoma (86)

Melanoma (1043)

Ocular Melanoma (111)

Uveal Melanoma (106)

Cutaneous Melanoma (86)

›

No biomarker	Mucosal Melanoma	No biomarker	Mucosal Melanoma	toripalimab-tpzi Sensitive: B - Late Trials toripalimab-tpzi Sensitive : B	toripalimab-tpzi Sensitive: B - Late Trials toripalimab-tpzi Sensitive : B
No biomarker	Mucosal Melanoma	No biomarker	Mucosal Melanoma	ALKS 4230 Sensitive: B - Late Trials ALKS 4230 Sensitive : B	ALKS 4230 Sensitive: B - Late Trials ALKS 4230 Sensitive : B
CDK4 amplification	Mucosal Melanoma	CDK4 amplification	Mucosal Melanoma	dalpiciclib Sensitive: C2 – Inclusion Criteria dalpiciclib Sensitive : C2	dalpiciclib Sensitive: C2 – Inclusion Criteria dalpiciclib Sensitive : C2
BRAF mutation	Mucosal Melanoma	BRAF mutation	Mucosal Melanoma	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
KIT mutation	Mucosal Melanoma	KIT mutation	Mucosal Melanoma	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
MDM2 amplification	Mucosal Melanoma	MDM2 amplification	Mucosal Melanoma	ipilimumab Resistant: C3 – Early Trials ipilimumab Resistant : C3	ipilimumab Resistant: C3 – Early Trials ipilimumab Resistant : C3
MDM4 amplification	Mucosal Melanoma	MDM4 amplification	Mucosal Melanoma	ipilimumab Resistant: C3 – Early Trials ipilimumab Resistant : C3	ipilimumab Resistant: C3 – Early Trials ipilimumab Resistant : C3
MDM2 amplification	Mucosal Melanoma	MDM2 amplification	Mucosal Melanoma	nivolumab + ipilimumab Resistant: C3 – Early Trials nivolumab + ipilimumab Resistant : C3	nivolumab + ipilimumab Resistant: C3 – Early Trials nivolumab + ipilimumab Resistant : C3
MDM2 amplification	Mucosal Melanoma	MDM2 amplification	Mucosal Melanoma	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3
MDM4 amplification	Mucosal Melanoma	MDM4 amplification	Mucosal Melanoma	nivolumab + ipilimumab Resistant: C3 – Early Trials nivolumab + ipilimumab Resistant : C3	nivolumab + ipilimumab Resistant: C3 – Early Trials nivolumab + ipilimumab Resistant : C3
MDM4 amplification	Mucosal Melanoma	MDM4 amplification	Mucosal Melanoma	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3
EGFR amplification	Mucosal Melanoma	EGFR amplification	Mucosal Melanoma	ipilimumab Resistant: C3 – Early Trials ipilimumab Resistant : C3	ipilimumab Resistant: C3 – Early Trials ipilimumab Resistant : C3